- Home
- KYMR vs HHH Comparison
KYMR vs HHH Comparison
Compare KYMR & HHH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KYMR
- HHH
- Stock Information
- Founded
- KYMR 2015
- HHH 2010
- Country
- KYMR United States
- HHH United States
- Employees
- KYMR N/A
- HHH N/A
- Industry
- KYMR Medicinal Chemicals and Botanical Products
- HHH Real Estate Investment Trusts
- Sector
- KYMR Health Care
- HHH Real Estate
- Exchange
- KYMR Nasdaq
- HHH Nasdaq
- Market Cap
- KYMR 3.1B
- HHH 3.3B
- IPO Year
- KYMR 2020
- HHH N/A
- Fundamental
- Price
- KYMR $44.91
- HHH $69.26
- Analyst Decision
- KYMR Strong Buy
- HHH Buy
- Analyst Count
- KYMR 16
- HHH 2
- Target Price
- KYMR $58.94
- HHH $80.50
- AVG Volume (30 Days)
- KYMR 875.7K
- HHH 492.2K
- Earning Date
- KYMR 08-06-2025
- HHH 08-06-2025
- Dividend Yield
- KYMR N/A
- HHH N/A
- EPS Growth
- KYMR N/A
- HHH N/A
- EPS
- KYMR N/A
- HHH 5.22
- Revenue
- KYMR $58,885,000.00
- HHH $1,793,533,000.00
- Revenue This Year
- KYMR $58.26
- HHH N/A
- Revenue Next Year
- KYMR N/A
- HHH $24.62
- P/E Ratio
- KYMR N/A
- HHH $13.23
- Revenue Growth
- KYMR N/A
- HHH 106.40
- 52 Week Low
- KYMR $19.45
- HHH $59.83
- 52 Week High
- KYMR $53.27
- HHH $87.77
- Technical
- Relative Strength Index (RSI)
- KYMR 56.82
- HHH 56.11
- Support Level
- KYMR $43.56
- HHH $68.15
- Resistance Level
- KYMR $45.83
- HHH $71.59
- Average True Range (ATR)
- KYMR 1.77
- HHH 1.37
- MACD
- KYMR -0.49
- HHH 0.27
- Stochastic Oscillator
- KYMR 51.65
- HHH 78.96
About KYMR Kymera Therapeutics Inc.
Kymera Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to reinventing the treatment of human disease through the development of, differentiated medicines that address health problems and that meaningfully improve patients' lives. It is committed to novel technologies to address targets that have known disease-causing biology, but which have not been drugged, or have been inadequately drugged, often based on limitations of existing technologies. Its approach is intended to discover and develop a new generation of medicines in a disease-agnostic manner. Its product pipelines are STAT6, TYK2, and IRAK4.
About HHH Howard Hughes Holdings Inc.
Howard Hughes Holdings Inc owns, manages, and develops commercial, residential, and mixed-use real estate throughout the USA. Its portfolio is strategically positioned to meet and accelerate development based on market demand, resulting in one of the strongest real estate platforms in the country. It operates through four business segments: Operating Assets, MPCs, Strategic Developments and Seaport.